When medication reduction is
not the right next step

Honest clinical advice includes saying not yet

There is a version of deprescribing advocacy that treats medication reduction as an unqualified good — something to pursue as soon as possible, regardless of circumstances. We do not hold that view.

Psychiatric medication has a role. For some people, in some circumstances, it is genuinely necessary — not as a permanent solution, but as a means of maintaining sufficient stability for life to be lived and inner work to happen. Removing it before the conditions are right does not serve the person. It creates distress, undermines confidence, and can set back a process that might otherwise succeed.

Our commitment is to honest clinical advice — which means that when we assess someone and conclude that reduction is not the right next step, we say so clearly. We also try to be specific about why, and about what we think the right next step actually is.

Acute psychiatric instability

The most unambiguous circumstance in which medication reduction is not appropriate is acute psychiatric instability. Active suicidal ideation, acute psychosis, severe depressive episode, acute mania — these states indicate the nervous system does not have the spare capacity to navigate medication change safely. Attempting to reduce during an acute episode risks compounding the crisis, not resolving it.

In these circumstances, the priority is stabilisation. That might mean the current medication at the current dose, an adjustment to the existing regimen, or in some cases additional clinical support. Once stability is meaningfully restored — not just a surface-level return to baseline, but a genuine settling of the nervous system — the question of reduction can be revisited.

Significant concurrent life stress

Bereavement, relationship breakdown, job loss, housing instability, legal proceedings — significant external stressors reduce the nervous system's reserve. The same medication reduction that would be manageable under stable conditions can be genuinely destabilising during a period of high external pressure, not because the person is incapable, but because the system is already under load.

This is not a reason to defer indefinitely — life rarely produces extended periods of complete calm, and waiting for perfect conditions can become an obstacle in itself. But it is a reason to assess carefully. When someone is carrying significant active stressors, the clinical question is whether beginning a taper now is likely to succeed, or whether addressing the immediate stressors first — or building more support around the person — would substantially improve the chances of the process going well.

Often the answer is to wait, or to begin with very small holding reductions rather than a full taper, maintaining the possibility of progress while protecting the nervous system from being asked to do too much at once.

Insufficient inner stability

As we describe in our explainer on medication stability and the nervous system, there is a distinction between the chemical stability provided by medication and inner stability — the nervous system's own regulatory capacity. Medication reduction is most likely to succeed when inner stability is present or actively developing, not when the medication is doing all of the stabilising work with nothing beneath it.

This is one of the most difficult clinical judgements in deprescribing. Inner stability is not always visible from the outside, and people frequently underestimate their own capacity. But there are clinical indicators — the degree of distress when doses are missed or delayed, the level of anxiety that surrounds the prospect of reduction, the presence or absence of meaningful support structures, the person's relationship with their own emotional experience — that inform a careful assessment of where the nervous system actually is.

When inner stability is genuinely insufficient, the appropriate response is not to abandon the goal of reduction but to focus on building the conditions that will support it. This might involve psychological work, changes to how the person manages stress and sleep, building relationships and support structures, or simply more time on the current dose. Reduction is a destination that requires a road to reach it.

Medication that is actively necessary

For some people and some conditions, psychiatric medication remains clinically necessary — not as a result of dependence or inertia, but because the underlying condition, without medication, produces a level of disturbance that substantially impairs the person's ability to function, maintain relationships, or stay safe.

This is a clinical reality that deprescribing advocacy sometimes obscures. Schizophrenia, bipolar disorder with severe episodes, and certain other conditions carry genuine risks when medication is reduced without sufficient inner stability, external support, or careful clinical oversight. In these cases, the question is not simply whether reduction is possible but whether the risk-benefit balance favours it at this point in this person's life.

Honest clinical assessment sometimes leads to the conclusion that a medication, or a particular dose of it, should continue for now — and possibly for a long time. That conclusion deserves to be reached through careful reflection and shared decision-making, not through prescribing inertia or the assumption that someone will be on medication forever. But it is a valid conclusion, and we do not shy away from it when the evidence points that way.

A previous very difficult attempt without resolution

When someone has had a seriously destabilising experience during a previous attempt at reduction — one that involved prolonged or severe distress, significant loss of function, or a major psychiatric crisis — that history warrants careful attention before trying again.

In most cases, as we explain in our page on why tapering is often harder than expected, a difficult previous experience reflects a method problem rather than a capacity problem. A different approach, at a slower pace with more support, would produce a different outcome. This is often true, and we approach previous difficult histories with this assumption first.

But where a previous attempt was genuinely catastrophic — where the destabilisation was profound and the recovery was prolonged — the appropriate response is to spend time building the conditions for a different experience before attempting again. That might mean a year or more focused on stabilisation, inner work, and nervous system recovery before the question of reduction is reopened.

When the desire to reduce is driven primarily by fear

Sometimes people want to reduce their medication not because they feel ready — not because inner stability is growing or life circumstances are favourable — but because they are frightened of the medication itself. Frightened of long-term side effects, frightened of dependency, frightened of what it means about them that they need it.

These fears are often understandable and sometimes clinically well-founded. Long-term side effects are real. Dependence is real. The feeling that medication has become a permanent part of one's identity, crowding out the possibility of functioning any other way, is a real and significant experience.

But fear is not a good guide for the timing of medication reduction. It tends to produce rushed decisions, inadequate preparation, and insufficient support — the precise conditions that make reduction more likely to fail. When the primary driver of the desire to reduce is fear, the most helpful response is usually to work with the fear directly — to examine what it is based on, to address the legitimate concerns within it, and to approach the question of reduction from a more grounded position once some of that fear has been metabolised.

What the right next step usually is

When reduction is not yet appropriate, there is nearly always something constructive that can happen instead. Saying "not yet" should always come with a clinical account of what "yes" would require — what conditions need to be in place, what work would help create them, and what a realistic pathway towards reduction might look like from where the person currently is.

For some people, the right next step is stabilisation — consolidating a period of calm, building confidence, and allowing the nervous system to recover from previous attempts or current stress. For others, it is psychological or therapeutic work that was never done alongside the medication. For others still, it is a careful review of the current medication regimen — not to reduce, but to ensure that what is being taken is the right thing at the right dose, and that nothing is being taken out of inertia that could be safely rationalised.

In every case, the aim is the same: to move the person closer to a position from which reduction, if that remains their goal, is more likely to succeed. The question "is now the right time?" is not a barrier. It is part of the clinical care.